Identification of Dual-Target Inhibitors for Epidermal Growth Factor Receptor and AKT: Virtual Screening Based on Structure and Molecular Dynamics Study

• Published in: Molecules (Basel, Switzerland) Vol. 28; no. 22; p. 7607
• Main Authors: Yang, Hanyu, Zhang, Zhiwei, Liu, Qian, Yu, Jie, Liu, Chongjin, Lu, Wencai
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-11-2023
• Subjects: AKT; Analysis; Binding sites; Breast cancer; Cancer; Cancer therapies; Care and treatment; Cell growth; Drug resistance; EGFR; Epidermal growth factor; HMDB; Hydrogen bonds; Kinases; Ligands; Lung cancer; Medical research; Molecular dynamics; Oncology, Experimental; Proteins; Simulation; Simulation methods; small molecule inhibitors; TCMIO
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules28227607

Epidermal growth factor EGFR is an important target for non-small cell lung (NSCL) cancer, and inhibitors of the AKT protein have been used in many cancer treatments, including those for NSCL cancer. Therefore, searching small molecular inhibitors which can target both EGFR and AKT may help cancer treatment. In this study, we applied a ligand-based pharmacophore model, molecular docking, and MD simulation methods to search for potential inhibitors of EGFR and then studied dual-target inhibitors of EGFR and AKT by screening the immune-oncology Chinese medicine (TCMIO) database and the human endogenous database (HMDB). It was found that TCMIO89212, TCMIO90156, and TCMIO98874 had large binding free energies with EGFR and AKT, and HMDB0012243 also has the ability to bind to EGFR and AKT. These results may provide valuable information for further experimental study.